Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Notes Payables (2025)

Historic Notes Payables for Iovance Biotherapeutics (IOVA) over the last 3 years, with Q3 2025 value amounting to $1.0 million.

  • Iovance Biotherapeutics' Notes Payables changed N/A to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year change of. This contributed to the annual value of $5.0 million for FY2011, which is N/A changed from last year.
  • Per Iovance Biotherapeutics' latest filing, its Notes Payables stood at $1.0 million for Q3 2025.
  • Over the past 5 years, Iovance Biotherapeutics' Notes Payables peaked at $1.0 million during Q1 2025, and registered a low of $1.0 million during Q1 2025.